- Home
- ADAG vs ARL Comparison
ADAG vs ARL Comparison
Compare ADAG & ARL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADAG | ARL |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.2M | 256.7M |
| IPO Year | 2020 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ADAG | ARL |
|---|---|---|
| Price | $2.81 | $15.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $9.91 | N/A |
| AVG Volume (30 Days) | ★ 277.3K | 3.7K |
| Earning Date | 08-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 206.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,014,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $129.59 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.70 |
| 52 Week Low | $1.44 | $12.42 |
| 52 Week High | $4.85 | $24.44 |
Technical Indicators
Market Signals| Indicator | ADAG | ARL |
|---|---|---|
| Relative Strength Index (RSI) | 34.86 | 48.60 |
| Support Level | $2.80 | $14.45 |
| Resistance Level | $3.19 | $15.85 |
| Average True Range (ATR) | 0.29 | 0.61 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 16.77 | 49.81 |
Price Performance
Historical ComparisonAbout ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
About ARL American Realty Investors Inc.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments: the acquisition, development, ownership and management of multifamily properties (Residential Segment) and the acquisition, ownership and management of commercial real estate properties (Commercial Segment). Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.